Rhizavidin

Rhizavidin is a dimeric, high-affinity biotin-binding protein from the bacterium Rhizobium etli. It differs from the classic avidins found in egg white or from streptavidin in its dimeric (not tetrameric) quaternary structure, lacking a key tryptophan residue in the biotin-binding loop that is typically crucial for high-affinity binding in other avidins[1][2][3][5][6][7]. The biotin-binding site in rhizavidin remains largely preformed and stable due to a disulfide bridge, enabling exceptional affinity for biotin despite its structural differences from tetrameric avidins[1][2]. Its precise physiological function in Rhizobium etli is not entirely clear, and there is no evidence to suggest that rhizavidin is a conventional therapeutic target (such as a receptor, enzyme, transporter, etc.) or that it has direct relevance to human disease or pharmacology[1][2][3]. Rhizavidin, along with other avidins, is of biotechnological interest for biotin-binding applications, but it is not a recognized molecular target in therapeutic contexts[3][7]. Key clarifications: - Rhizavidin is not a conventional drug target, receptor, or enzyme but a biotechnological tool protein[1][2][3][7]. - No known drugs interact with it, and it is not used clinically as a biomarker or therapeutic target. - No common aliases or abbreviations are established beyond its canonical name. - There are no reported disease associations or safety concerns for therapeutic use. If you are seeking recognized drug targets, rhizavidin does not qualify under standard definitions.